NEUROGAIT: Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Sponsor

Henri Mondor University Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06107556

Collaborator

(none)

100

Enrollment

Location

8.4

Anticipated Duration (Months)

11.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Condition or Disease	Intervention/Treatment	Phase
Stroke Walking, Difficulty Spasticity/Paresis	Diagnostic Test: Gait analysis

Detailed Description

After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Study Design

Study Type:

Observational

Anticipated Enrollment :

100 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Anticipated Study Start Date :

Oct 19, 2023

Anticipated Primary Completion Date :

Oct 19, 2023

Anticipated Study Completion Date :

Jun 30, 2024

Outcome Measures

Primary Outcome Measures

Coefficient of antagonist activation [1 year]
The coefficient of antagonist activation of gastrocnemius medialis and soleus was calculated from EMG data by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Adult
Person who performed tridimensional gait analysis in laboratory
Person who had a stroke at least 6 months before the gait analysis

Exclusion Criteria:

Any other neurological pathology or gait disorders
Botulinum toxin injection in the last 3 months before the gait analysis

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Laboratoire Analyse et Restauration du Mouvement	Créteil		France

Sponsors and Collaborators

Henri Mondor University Hospital

Investigators

Principal Investigator: Emilie Hutin, Hôpitaux Universitaires Henri Mondor

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Emilie Hutin, Director, Henri Mondor University Hospital

ClinicalTrials.gov Identifier:

NCT06107556

Other Study ID Numbers:

2023-A02258-37

First Posted:

Oct 30, 2023

Last Update Posted:

Oct 30, 2023

Last Verified:

Oct 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Paresis

Trauma, Nervous System

Mobility Limitation

Study Results

No Results Posted as of Oct 30, 2023